妊娠期癌症患者多西他赛、紫杉醇、多柔比星和表柔比星的群体药代动力学研究
基于INCIP网络数据,采用非线性混合效应模型定量比较妊娠与非妊娠癌症患者中多西他赛、紫杉醇、多柔比星和表柔比星的药代动力学变化。研究发现妊娠期四种药物的中央和外周分布容积典型增加,多西他赛、多柔比星和紫杉醇的清除率升高导致暴露降低;但鉴于个体间变异,这些变化不直接支持剂量调整,并强调需研究妊娠期化疗的疗效。
要点
- 妊娠期多西他赛、紫杉醇、多柔比星和表柔比星的分布容积典型增加
- 妊娠期多西他赛、多柔比星和紫杉醇清除率升高,暴露低于非妊娠患者
- 药代动力学变化不直接 warrant 剂量调整,但需进一步研究妊娠期化疗疗效
核心结论
- 妊娠引起的药代动力学变化不直接 warrant 对所研究药物的剂量调整,但强调需研究妊娠期化疗的疗效。
研究设计与样本
- 基于INCIP网络9例多西他赛、20例紫杉醇、22例多柔比星和16例表柔比星妊娠癌症患者的药代动力学数据,结合非妊娠患者数据,建立非线性混合效应模型评估固定妊娠效应和孕龄协变量。
主要发现
- 妊娠患者多西他赛、紫杉醇、多柔比星和表柔比星的中央和外周分布容积典型增加。
- 妊娠患者多西他赛、多柔比星和紫杉醇的清除率升高,导致暴露低于非妊娠患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Based on reassuring short-term foetal and maternal safety data, there is an increasing trend to administer chemotherapy during the second and third trimesters of pregnancy. The pharmacokinetics (PK) of drugs might change as a result of several physiological changes that occur during pregnancy, potentially affecting the efficacy and safety of chemotherapy. OBJECTIVE: With this analysis, we aimed to quantitatively describe the changes in the PK of docetaxel, paclitaxel, doxorubicin and epirubicin in pregnant women compared with non-pregnant women. METHODS: PK data from 9, 20, 22 and 16 pregnant cancer patients from the International Network of Cancer, Infertility and Pregnancy (INCIP) were available for docetaxel, paclitaxel, doxorubicin and epirubicin, respectively. These samples were combined with available PK data from non-pregnant patients. Empirical non-linear mixed-effects models were developed, evaluating fixed pregnancy effects and gestational age as covariates. RESULTS: Overall, 82, 189, 271, and 227 plasma samples were collected from pregnant patients treated with docetaxel, paclitaxel, doxorubicin and epirubicin, respectively. The plasma PK data were adequately described by the respective models for all cytotoxic drugs. Typical increases in central and peripheral volumes of distribution of pregnant women were identified for docetaxel, paclitaxel, doxorubicin and epirubicin. Additionally, docetaxel, doxorubicin and paclitaxel clearance were increased in pregnant patients, resulting in lower exposure in pregnant women compared with non-pregnant patients. CONCLUSION: Given the interpatient variability, the identified pregnancy-induced changes in PK do not directly warrant dose adjustments for the studied drugs. Nevertheless, these results underscore the need to investigate the efficacy of chemotherapy, when administered during pregnancy.
引用
- Janssen JM, Van Calsteren K, Dorlo TPC, et al. Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). Clin Pharmacokinet. 2021. PMID: 33506375. doi:10.1007/s40262-020-00961-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。